Pages
Home
MIDDLE EAST
AFRICA
Saturday, 18 July 2020
Glecaprevir–pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies— a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2) - The Lancet
Glecaprevir–pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies— a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)
The Lancet
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment